Citius Oncology, Inc.
NASDAQ:CTORDrug Manufacturers - General
+$0.03 today
- Market cap
- $51.83M
- Beta
- 3.42
- P/E (TTM)
- -1.6
- EPS (TTM)
- -$0.42
Volume 0.15M
Average 0.12M
CTOR EPS (Diluted)
Earnings per share assuming conversion of dilutive securities such as options and convertible instruments.
Citius Oncology, Inc.NASDAQ: CTOR
EPS (Diluted) · Q2 FY2026 · quarter ended Mar 2026
EPS (Diluted) remains negative
Q2 FY2026 EPS (Diluted) was -$0.27, compared with -$0.11 a year earlier. Trailing-twelve-month EPS (Diluted) was -$0.47.
Context
- EPS (Diluted) grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether EPS (Diluted) reaches the consensus estimate from 1 analysts of -$0.52 (-52.9%) for the fiscal year ending Sep 2026, a slowdown from the -13.3% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$0.27-326.5% QoQ
- Last fiscal yearSep 2025
- -$0.34-13.3% YoY
- LTMMar 2026
- -$0.47-26.5% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -145.5% | +46.7% | +192.1 pp |
| 1 year | -13.3% | -52.9% | -39.6 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EPS (Diluted) history
USD · from the income statement
- Latest · FY2025
- (0.34) USD
- Year-over-year change
- -13.3%
| Period | Period end | EPS (Diluted) | YoY change |
|---|---|---|---|
| FY2025 | 2025-09-30 | (0.34) | -13.3% |
| FY2024 | 2024-09-30 | (0.30) | -57.9% |
| FY2023 | 2023-09-30 | (0.19) | -149.0% |
| FY2022 | 2022-09-30 | (0.08) | — |
EPS (Diluted) vs competitors
How CTOR compares with its peers on the latest reported figures
- CTOR's LTM Mar 2026 EPS (Diluted) of -$0.47 is the 2nd highest of the 10 companies compared; the peer median is -$3.38.
- Its year-over-year change of -26.5% is the 7th highest of 10, against a peer median of +45.3%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Mar 2026 | $0.24 | +118.6% | — | |
CTORCitius Oncology, Inc. | LTM Mar 2026 | -$0.47 | -26.5% | — |
| LTM Mar 2026 | -$0.58 | +88.1% | — | |
ACTUActuate Therapeutics Inc | LTM Mar 2026 | -$0.99 | +45.3% | — |
| LTM Mar 2026 | -$1.09 | +26.8% | — | |
| LTM Mar 2026 | -$3.38 | -134.7% | — | |
| LTM Mar 2026 | -$4.58 | +66.8% | — | |
| LTM Mar 2026 | -$5.17 | +48.2% | — | |
| LTM Mar 2026 | -$38.87 | -148.5% | — | |
| LTM Mar 2026 | -$838.86 | -2659.4% | — | |
| Peer median (excluding CTOR) | -$3.38 | +45.3% | — | |
Competitors are the stored peer set for CTOR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2022 Sep 2022 | FY2023 Sep 2023 | FY2024 Sep 2024 | FY2025 Sep 2025 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — |
| Research & Development | 6.86M | 4.24M | 4.93M | 6.42M |
| Selling, General & Admin | 2.86M | 7.88M | 15.65M | 17.1M |
| Operating Expenses | 9.71M | 12.12M | 20.57M | 23.52M |
| Depreciation & Amortization | 9.71M | 0 | 0 | 0 |
| EBITDA | 0 | (12.12M) | (20.57M) | (23.49M) |
| EBITDA Margin | — | — | — | — |
| Operating Income | (9.71M) | (12.12M) | (20.57M) | (23.52M) |
| Operating Margin | — | — | — | — |
| Interest Income | 0 | 0 | 0 | 36.37K |
| Interest Expense | 0 | 0 | 0 | 218.03K |
| Other Income / Expenses | 0 | 0 | 0 | (181.66K) |
| Income Before Tax | (9.71M) | (12.12M) | (20.57M) | (23.7M) |
| Pre-Tax Margin | — | — | — | — |
| Income Tax Expense | 1.15M | 576K | 576K | 1.06M |
| Net Income | (10.87M) | (12.7M) | (21.15M) | (24.76M) |
| Net Margin | — | — | — | — |
| EPS (Basic) | (0.08) | (0.19) | (0.30) | (0.34) |
| EPS (Diluted) | (0.08) | (0.19) | (0.30) | (0.34) |
| Weighted Avg Shares | 90.16M | 89.48M | 71.55M | 73.27M |
| Weighted Avg Shares (Diluted) | 90.16M | 89.48M | 71.55M | 73.27M |
Citius Oncology, Inc.
NASDAQ:CTOR
Intrinsic Alpha fair value
Locked
Current Price
$0.56
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.